[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl]-piperazin-1-ylmethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: [(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl]-piperazin-1-ylmethanone
• 化学式: C₁₈H₂₆N₂O₃
• 分子量: 318.4
• InChiKey: UBQNZKMELMBKHG-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS
  申请人：Sulfateq B.V.

  公开号：EP3672593A1

  公开（公告）日：2020-07-01
• [EN] MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS<br/>[FR] MÉDICAMENTS POUR LE TRAITEMENT DE MALADIES OU DE TROUBLES LIÉS À LA VASOCONSTRICTION
  申请人：SULFATEQ BV

  公开号：WO2019038361A1

  公开（公告）日：2019-02-28

  The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative for use in the prophylactic or treatment of vasoconstriction related disorders or conditions. A preferred 6-chromanol derivative is (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-l-yl)methanone; N-(benzyl)-6-hydroxy- 2,5,7, 8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2- carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts thereof.